PDCD1 and non-small cell lung carcinoma: There is growing evidence that anti‐PD‐1 and anti‐PD‐L1 therapy can lead to durable disease response in a subgroup of patients with NSCLC, even in those who were heavily pretreated for whom scant treatment options exist.